- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular avenues in targeted doxorubicin cancer therapy
Authors
Keywords
-
Journal
Future Oncology
Volume 16, Issue 11, Pages 687-700
Publisher
Future Medicine Ltd
Online
2020-04-07
DOI
10.2217/fon-2019-0458
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway
- (2019) Hong Dai et al. BIOSCIENCE REPORTS
- The emergence of drug resistance to targeted therapies: Clinical evidence
- (2019) Ana Bela Sarmento-Ribeiro et al. DRUG RESISTANCE UPDATES
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- Macrophage flipping from foe to friend: A matter of interest in breast carcinoma heterogeneity driving drug resistance
- (2018) Ishita Tandon et al. CURRENT CANCER DRUG TARGETS
- Suppression of p53R2 gene expression with specific siRNA sensitizes HepG2 cells to doxorubicin
- (2018) Ako Azimi et al. GENE
- Inhibition of novel GCN5-ATM axis restricts the onset of acquired drug resistance in leukemia
- (2018) Sameer Salunkhe et al. INTERNATIONAL JOURNAL OF CANCER
- MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2
- (2018) Lisha Zhao et al. Redox Biology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells
- (2017) Tassarut Chaisit et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway
- (2017) Hongyu Shen et al. GENE
- Chitosan-based nanocomplexes for simultaneous loading, burst reduction and controlled release of doxorubicin and 5-fluorouracil
- (2017) Antonio Di Martino et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Graphene quantum dots for cancer targeted drug delivery
- (2017) Daniela Iannazzo et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro
- (2017) Dmitriy Smolensky et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity
- (2017) Jiye Wang et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
- (2017) Bennett E Levis et al. LANCET ONCOLOGY
- HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia
- (2017) S Tharkar-Promod et al. LEUKEMIA
- Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells
- (2017) Esther Martinez-Font et al. MOLECULAR CANCER THERAPEUTICS
- Poly(γ-glutamic acid)-coated lipoplexes loaded with Doxorubicin for enhancing the antitumor activity against liver tumors
- (2017) Na Qi et al. Nanoscale Research Letters
- Photothermal-triggered control of sub-cellular drug accumulation using doxorubicin-loaded single-walled carbon nanotubes for the effective killing of human breast cancer cells
- (2017) Yunok Oh et al. NANOTECHNOLOGY
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Combined effects of furanodiene and doxorubicin on the migration and invasion of MDA-MB-231 breast cancer cells in vitro
- (2017) Zhang-Feng Zhong et al. ONCOLOGY REPORTS
- B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells
- (2017) Xiaoxiao Yao et al. TUMOR BIOLOGY
- The significance of a nineteenth century definition in the era of genomics: linitis plastica
- (2017) Annamaria Agnes et al. World Journal of Surgical Oncology
- Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
- (2017) Krysta Mila Coyle et al. Biomed Research International
- Poly(γ-glutamic acid)-coated lipoplexes loaded with Doxorubicin for enhancing the antitumor activity against liver tumors
- (2017) Na Qi et al. Nanoscale Research Letters
- MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma
- (2017) Yin-Ping Fan et al. Molecular Therapy-Nucleic Acids
- Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer
- (2017) Reva K. Basho et al. JAMA Oncology
- Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells
- (2017) Simon Chewchuk et al. PLoS One
- Monitoring doxorubicin cellular uptake and trafficking using in vitro Raman microspectroscopy: short and long time exposure effects on lung cancer cell lines
- (2016) Zeineb Farhane et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Cardiotoxicity of anthracycline therapy: current perspectives
- (2016) Mihaela Valcovici et al. Archives of Medical Science
- Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II
- (2016) Ka C. Lee et al. BIOCHEMICAL PHARMACOLOGY
- An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL
- (2016) Y. Mai et al. BLOOD
- Unfolded Protein Response Promotes Doxorubicin-Induced Nonsmall Cell Lung Cancer Cells Apoptosis via the mTOR Pathway Inhibition
- (2016) Xiaofang Zhao et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- HOXC10 Expression Supports the Development of Chemotherapy Resistance by Fine Tuning DNA Repair in Breast Cancer Cells
- (2016) H. Sadik et al. CANCER RESEARCH
- Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment
- (2016) Thomas M. Bodenstine et al. CELL CYCLE
- Small Molecules Targeting Ataxia Telangiectasia and Rad3-Related (ATR) Kinase: An Emerging way to Enhance Existing Cancer Therapy
- (2016) Martin Andrs et al. CURRENT CANCER DRUG TARGETS
- Towards 99mTc-based imaging agents with effective doxorubicin mimetics: a molecular and cellular study
- (2016) S. Imstepf et al. DALTON TRANSACTIONS
- Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing
- (2016) Yasemin Saygideger Kont et al. DNA REPAIR
- Influence of nucleotide excision repair on mitoxantrone cytotoxicity
- (2016) Jaqueline Cesar Rocha et al. DNA REPAIR
- New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy
- (2016) Alberto A. Gabizon et al. DRUG RESISTANCE UPDATES
- Furanodiene enhances the anti-cancer effects of doxorubicin on ERα-negative breast cancer cells in vitro
- (2016) Zhang-Feng Zhong et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway
- (2016) Hongyu Shen et al. GENE
- Tunable doxorubicin release from polymer-gated multiwalled carbon nanotubes
- (2016) Alessandro Pistone et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors
- (2016) Eva Koziolová et al. JOURNAL OF CONTROLLED RELEASE
- Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
- (2016) Joel G. Turner et al. Journal of Hematology & Oncology
- Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and Formaldehyde
- (2016) Benjamin L. Barthel et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Microscope against Cell Theory: Cancer Research in Nineteenth-Century Parisian Anatomical Pathology
- (2016) Laurent Loison JOURNAL OF THE HISTORY OF MEDICINE AND ALLIED SCIENCES
- Oxidative stress does not play a primary role in the toxicity induced with clinical doses of doxorubicin in myocardial H9c2 cells
- (2016) Tareck Rharass et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer
- (2016) N. A. Jabbour-Leung et al. MOLECULAR CANCER THERAPEUTICS
- Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin
- (2016) Mengjie Rui et al. MOLECULAR PHARMACEUTICS
- Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma
- (2016) Miodrag Dragoj et al. CELLULAR ONCOLOGY
- P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors
- (2016) Joanna Kopecka et al. Oncotarget
- CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers
- (2016) Vino T. Cheriyan et al. Oncotarget
- Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
- (2016) Shan Guan et al. Oncotarget
- Overcoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption
- (2016) Jong Seong Ha et al. Scientific Reports
- Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance
- (2016) Prema Robinson et al. Biomed Research International
- Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth
- (2015) Yong Zhao et al. BIOCHEMICAL PHARMACOLOGY
- Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2-induced doxorubicin resistance in breast cancer cells
- (2015) Zheqi Li et al. CANCER SCIENCE
- Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest
- (2015) Mariko Morii et al. CELL BIOLOGY INTERNATIONAL
- L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation
- (2015) Waldemar Wagner et al. Cell Communication and Signaling
- Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells
- (2015) Ji Na Kong et al. INTERNATIONAL JOURNAL OF CANCER
- Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal
- (2015) Shulin Xiang et al. JOURNAL OF PINEAL RESEARCH
- Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling
- (2015) Jessica M Foley et al. Journal of Translational Medicine
- Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins
- (2015) Cláudia Gonçalves et al. LIFE SCIENCES
- Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia
- (2015) CHENJIAO YAO et al. Molecular Medicine Reports
- Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells
- (2015) JINPENG LI et al. Molecular Medicine Reports
- Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines
- (2015) Emiliana Perillo et al. Oncotarget
- Phosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis
- (2015) Jianxun Wang et al. Oncotarget
- Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
- (2015) Zuzanna Baranski et al. Oncotarget
- Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells
- (2015) Sebastian Czaplinski et al. Oncotarget
- Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells
- (2015) Kamolporn Amornsupak et al. BMC CANCER
- New Potent and Selective Inhibitor of Pim-1/3 Protein Kinases Sensitizes Human Colon Carcinoma Cells to Doxorubicin
- (2014) Pascale Moreau et al. Anti-Cancer Agents in Medicinal Chemistry
- Synthesis of Poly[N-(2-hydroxypropyl)methacrylamide] Conjugates of Inhibitors of the ABC Transporter That Overcome Multidrug Resistance in Doxorubicin-Resistant P388 Cells in Vitro
- (2014) V. Šubr et al. BIOMACROMOLECULES
- Epistemology of the origin of cancer: a new paradigm
- (2014) Björn LDM Brücher et al. BMC CANCER
- Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway
- (2014) Ting Chen et al. CANCER BIOLOGY & THERAPY
- Methylation-regulated miR-149 modulates chemoresistance by targeting GlcNAcN-deacetylase/N-sulfotransferase-1 in human breast cancer
- (2014) Dong-Xu He et al. FEBS Journal
- TGFβ Induces “BRCAness” and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes
- (2014) Liang Liu et al. MOLECULAR CANCER RESEARCH
- Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line
- (2014) Enrico Capobianco et al. PLoS One
- N-Aroyl Indole Thiobarbituric Acids as Inhibitors of DNA Repair and Replication Stress Response Polymerases
- (2013) Grace E. Coggins et al. ACS Chemical Biology
- DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin
- (2013) Wojciech M. Ciszewski et al. BREAST CANCER RESEARCH AND TREATMENT
- Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
- (2013) J G van Oosterwijk et al. BRITISH JOURNAL OF CANCER
- The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress
- (2013) Ekaterina R Kim et al. CELL CYCLE
- Nanomedicines as Cancer Therapeutics: Current Status
- (2013) Sohail Akhter et al. CURRENT CANCER DRUG TARGETS
- Mad1 mediates hypoxia-induced doxorubicin resistance in colon cancer cells by inhibiting mitochondrial function
- (2013) Kumsun Cho et al. FREE RADICAL BIOLOGY AND MEDICINE
- Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin
- (2013) VASYL F. CHEKHUN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Doxorubicin-Loaded Cyclic Peptide Nanotube Bundles Overcome Chemoresistance in Breast Cancer Cells
- (2013) Yongzhong Wang et al. Journal of Biomedical Nanotechnology
- Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells
- (2013) Martin Werner et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress
- (2013) C. Bassi et al. SCIENCE
- Increased Expression of P-Glycoprotein and Doxorubicin Chemoresistance of Metastatic Breast Cancer Is Regulated by miR-298
- (2012) Lili Bao et al. AMERICAN JOURNAL OF PATHOLOGY
- An Inhibitor of Nonhomologous End-Joining Abrogates Double-Strand Break Repair and Impedes Cancer Progression
- (2012) Mrinal Srivastava et al. CELL
- Phosphorylation of IκBα at Serine 32 by T-lymphokine-activated Killer Cell-originated Protein Kinase Is Essential for Chemoresistance against Doxorubicin in Cervical Cancer Cells
- (2012) Jung-Hwan Park et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- α2β1 Integrin Promotes Chemoresistance against Doxorubicin in Cancer Cells through Extracellular Signal-regulated Kinase (ERK)
- (2012) Dalila Naci et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2
- (2012) Francesca Fornari et al. JOURNAL OF PATHOLOGY
- Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells
- (2012) Elisa Latorre et al. Molecular Cancer
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Smac Mimetic SM-164 Potentiates APO2L/TRAIL- and Doxorubicin-Mediated Anticancer Activity in Human Hepatocellular Carcinoma Cells
- (2012) Shuijun Zhang et al. PLoS One
- Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
- (2011) Niranjan Awasthi et al. BMC CANCER
- Both XPA and DNA polymerase eta are necessary for the repair of doxorubicin-induced DNA lesions
- (2011) Maria Carolina S. Moraes et al. CANCER LETTERS
- SMAC Mimetic (JP1201) Sensitizes Non-Small Cell Lung Cancers to Multiple Chemotherapy Agents in an IAP-Dependent but TNF- -Independent Manner
- (2011) R. M. Greer et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Epigenetic modifications in cancer
- (2011) R Kanwal et al. CLINICAL GENETICS
- Origins and Mechanisms of miRNAs and siRNAs
- (2009) Richard W. Carthew et al. CELL
- Synthesis and DNA-binding affinity studies of glycosylated intercalators designed as functional mimics of the anthracycline antibiotics
- (2009) Wei Shi et al. ORGANIC & BIOMOLECULAR CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now